Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma

American Journal of Dermatopathology

Volumn 21, Issue 1, 1999, Pages 72-74

  Arush, Miryam Weyl Ben ^a   Stein, Moshe E ^a,c   Kuten, Avraham ^a   Meller, Izhak ^b   Moses, Martha ^b   Drumea, Keren ^a   Haim, Nissim ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Etoposide; Ifosfamide; Osteosarcoma; Poor risk; Salvage regimen

Indexed keywords

EID: 33646950993     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Marcove R, Mike V, Haych Jr, et al. Osteogenic sarcoma under the age of twenty-one: a review of 145 operative cases. J Bone Joint Surg Am 1970;52:411-22.
2. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteocenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
3. Tabore MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pédiatrie patients previously with intensive chemotherapy. J Clin Oncol 19; 12:2614-20.
4. Picci P, Sanglorgt L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12:2699-705.
5. Link MP, Eilber F. Osteosarcoma. In: De Vita VT, ed. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott, 1993:841-66.
6. Wada T, Isu K, Takeda N, et al. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology 1996; 53:221-7.
7. Bacci G, Ricci P, Pignatti G, et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the experience at the Rizzoli Institute. Clin Orlhop 1991;270:87-98.
8. Bacci G, Ricci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72:3227-38.
9. Saleter G, Hoei J, Stenwig AE, et al. Systemic relapse of patients with osteocenic sarcoma: prognostic factors for long-term survival. Cancer 1995;75:1084-93.
10. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12:423-31.
11. Huvos A, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Paihol Lab Meil 1977:101:14-8.
12. Hams MB, Cantor AB, Corin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pédiatrie patients with recurrent disease vs patients previously untreateda Pédiatrie Oncoloay Group study. Med Pediatr Oncol 1995; 24:87-92.
13. Elias AD, Eder JP, Shea T, et al. High-dose ifosfamide with MESNA uroprotection: a phase I study. J Clin Oncol 1990; 8:170-8.
14. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (Coss-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6:329-37.